Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 10 March 2026
Revised 22 April 2026
Accepted 14 May 2026

Natural Resources for Human Health 2026, Vol. 6 (3): 496–503

KEYWORDS:
Flaxseed; Chapati; Dyslipidemia; Triglycerides; Functional food; Alpha-linolenic acid; LDL cholesterol; Cardiometabolic health; Dietary fiber; Randomized controlled trial.

Cardiometabolic Benefits of Flaxseed-Enriched Chapati in Adults with Dyslipidemia

Aashish A[1], Surendar P. B.[2], Mashrab Usmanov[3], Mahendran Arumugam[4], Uma Maheswari M.[5], Maneesh Jaiswal[6], Ankit Sachdeva[7]

[1]Department of Cardiology, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552, India, aashish@maher.ac.in
[2]Department of Cardiology, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552, India, surendarpb@maher.ac.in
[3]Jizzakh State Pedagogical University, Jizzakh, Uzbekistan, mashrabusmonov79@gmail.com
[4]Center for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India, mahendrana.sdc@saveetha.com
[5]Assistant Professor, Department of Cardiac Technology, School of Allied Health Sciences, Vinayaka Mission's Chennai Campus, Vinayaka Mission's Research Foundation (Deemed to be University), Tamil Nadu, India, uma14297@gmail.com
[6]Professor, Department of Pharmacy, Vivekananda Global University, Jaipur, Rajasthan, India, maneesh.jaiswal@vgu.ac.in
[7]Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab 140401, India, ankit.sachdeva.orp@chitkara.edu.in

ABSTRACT:

Background: The incorporation of flaxseed into a traditional staple can enhance adherence and relevance in populations over long-term.

Objective: To compare two daily chapatis fortified with 20 g milled flaxseed to isocaloric standard wheat chapatis with the help of a randomized controlled trial.

Methods: The protocol draft consisted of 90 experimental units or subjects of adults with untreated mild-to-moderate dyslipidemia. The intervention was given or subjected to 12 weeks. The main result was serum triglycerides, and secondary evaluation of LDL cholesterol, HDL cholesterol, systolic blood pressure, high-sensitivity C-reactive protein. Standard laboratory, clinical, or food-analysis methods were used and between-condition effects were tested at two-sided tests at $\alpha=0.05$.

Results: Flaxseed-enriched chapati reduced triglycerides by 45 ± 24 mg/dL compared with 7 ± 21 mg/dL after standard chapati ($p<0.001$). LDL cholesterol fell by 18 mg/dL, hs-CRP by 0.8 mg/L, and systolic pressure by 5.6 mmHg in the intervention group, with 92% adherence. The direction and magnitude of the dummy findings were internally consistent across primary and secondary endpoints, and tolerability or assay-quality criteria remained acceptable.

Natural Resources for Human Health
eISSN: 2583-1194

Conclusion: The example dataset suggests that two daily chapatis enriched with 20 g milled flaxseed could produce a meaningful improvement in serum triglycerides through alpha-linolenic acid, lignans, and viscous fiber acting on lipid metabolism, bile-acid handling, and vascular inflammation. These findings are intended solely as a complete manuscript-development example and require replacement with ethically generated, independently verified observations before scientific submission.

1. INTRODUCTION

Cardiometabolic Benefits of Flaxseed-Enriched Chapati in Adults With Dyslipidemia addresses an important question at the interface of experimental pharmacology, nutritional science, and translational health research. Directly relevant published work has established a scientific basis for evaluating two daily chapatis enriched with 20 g milled flaxseed in relation to serum triglycerides [1]. Nevertheless, variations in preparation, exposure, comparator selection, and outcome definition continue to limit confident comparison across studies.

There is a second line of evidence as to the biological plausibility of this current hypothesis. Functional or biochemical activity in line with the direction of benefit proposed has been reported in prior studies of flaxseed and nearly allied interventions [2]. These observations not only justify formal testing but also do not negate the need of standardized materials and preset standards of analysis.

The broader natural-product and functional-food literature demonstrates that reproducibility is dependent upon chemical characterization, processing conditions, dose, biological matrix, and stability of active components [3]. In the current research, two daily chapatis supplemented with 20 g of milled flaxseed was thus considered a research-grade intervention as opposed to an indeterminate traditional or commercial preparation.

The suggested mechanism includes alpha-linolenic acid, lignan, and viscous fiber that have an effect on lipid metabolism, bile-acid management, and vascular inflammation. It has been reported that associated biological responses are typically associated with interacting redox, inflammatory, metabolic, microbial, enzymatic or differentiation pathways as opposed to an individual target [4]. The combination of measuring a primary functional endpoint and mechanistic markers can thus give a more consistent interpretation.

The outcome assessment also needs techniques to be used in the study model. Standardized sample handling, validated analytical procedures, adequate controls and prespecified interpretation limits are stressed by established laboratory or clinical methodology [5]. These principles informed the choice of serum triglycerides as the main outcome and the secondary outcomes, which accompany it.

The most compelling changes in serum triglycerides are those that are concordantly accompanied by changes in LDL cholesterol and HDL cholesterol. Similar studies have shown how the combination of functional and biochemical and structural results is important in the assessment of complex botanical, microbial, or food-based interventions [6].

Safety and quality are also crucial. Natural origin does not ensure uniform composition or lack of adverse effects, contaminants, interactions or degradation and published pharmacovigilance and quality-control data suggests incorporation of these factors at the earliest stage of product development [7].

Lastly, there should be transparency in the study design to minimize bias. Randomization, blinding (where possible), replication, full accounting of exclusions and reporting of effect estimates are recommended by guidance and prior methodological studies applicable to the current experimental model instead of use of p-values alone [8].

Although there is available evidence, there is a dearth of literature that has combined a well-defined two daily chapati with 20 g milled flaxseed, a proper comparator, a prespecified primary endpoint, and supporting mechanistic or feasibility results among adults with untreated mild-moderate dyslipidemia. The purpose of this experiment was thus to ascertain the influence of 20 g

of flaxseed milled to two daily chapatis on serum triglycerides in comparison to isocaloric standard wheat chapatis. Secondary outcomes included measuring LDL cholesterol, HDL cholesterol, systolic blood pressure, and quality or safety outcomes.

2. MATERIALS AND METHODS

2.1 Study design and setting

This paper outlines a prespecified, parallel-group controlled trial of adults with untreated mild-to-moderate dyslipidemia. The intended sample size of 90 experimental units or participants was designed to make comparisons of two daily chapatis fortified with 20 g milled flaxseed against an isocaloric standard of wheat chapati. The time of observation was 12 weeks. The numbers within this manuscript are all dummy/example data developed to draft, demonstrate statistically, construct tables, and prepare graphs; they do not reflect numbers of observations of a completed investigation. The design, however, adheres to realistic laboratory or clinical workflows such that the draft may be later transformed to a suitable protocol to be approved and substituted with actual measurements.

2.2 Participants

The potential subjects were adults or adolescents who fit the target population: adults with mild-to-moderate dyslipidemia that is untreated. To be included, one had to have stable health or a stable background treatment, a willingness to continue with a normal diet and activity, and the capability of attending all assessment visits. The exclusion criteria were pregnancy, significant organ disease, the use of antibiotics or probiotics within two months where applicable, intake of other supplements that might affect the key outcome, allergy to the study components, or involvement in another intervention study. Written informed consent and, where applicable, assent and guardian consent would be mandatory for a real trial.

2.3 Allocation, intervention, and randomization

Variable block sizes were used to conceptually randomized the participants 1:1 and the allocation was hidden within the sequentially numbered opaque envelopes or electronic mechanism. The intervention group received two daily chapatis enriched with 20 g milled flaxseed; the control group received isocaloric standard wheat chapatis. They were instructed to continue with habitual diet, medication and physical activity, and the number of unused products and daily logs were estimated to determine adherence.

2.4 Outcome assessment

The primary outcome was serum triglycerides expressed as mg/dL. Secondary outcomes included LDL cholesterol, HDL cholesterol, systolic blood pressure, high-sensitivity C-reactive protein. The measurements were to be carried out at baseline and follow up or between concentration and time conditions depending on the design. Measurements were conducted as per commercial kit procedures or standardized analysis procedures, and the measurements were done twice in cases where the coefficient of variation was greater than 10%. Clinical measurements followed a standardized rest period, and the results of food-products were evaluated under the controlled conditions of serving.

2.5 Quality assurance and control of bias

Sample labeling, timing windows, calibration, data entry and protocol deviations were defined by a written laboratory or trial manual. Where the format of the intervention allowed it, outcome assessors were blinded. Ten percent conceptual rechecks of records were made against source data and only the analytical runs were accepted when calibration and quality-control samples were within predefined limits. The primary complete-case display did not replace missing values; sensitivity analyses employed an intention-to-treat framework or model-based estimation where applicable.

2.6 Sample-size rationale

The sample of 90 units was chosen because it is a realistic sample size to develop a manuscript. In a real study, the calculation ought to be substituted by one of a pilot-based standard deviation, and the smallest difference in serum triglycerides that is clinically or biologically significant. It should include the final calculation, which should give two-sided $\alpha=0.05$, desired power of at least 80%, ratio of allocations, expected attrition or unuseful assays and any corrections on repeated measures or clustering or multiple primary comparisons.

2.7 Statistical analysis

When the data were approximately normally distributed, continuous data were summarized as mean ± standard deviation and when skewed, as median with interquartile range. The outcomes were categorical that were presented in the form of number and percentage. Independent t tests, Mann-Whitney tests, chi-square tests, or Fisher exact tests were used as between-group baseline comparisons. Primary outcomes were assessed with analysis of covariance, repeated-measures analysis, mixed-effects models, one-way analysis of variance with multiplicity-adjusted post hoc comparisons, or nonparametric equivalents according to design. Effect estimates were accompanied by 95% confidence intervals. Correlations used Pearson or Spearman coefficients. All tests were two-sided, and $p<0.05$ was considered statistically significant. Analyses were conceptually performed in a current statistical package with an auditable syntax file.

3. RESULTS

The analysis included the full dummy/example dataset specified for the randomized parallel-group controlled trial. Baseline characteristics, assay controls, or starting values were balanced across comparison conditions, and no predefined quality-control run was rejected. The tables present mean ± standard deviation unless another summary is stated. Because the data are illustrative, participant flow, assay exclusions, and p-values were generated to be statistically coherent rather than to represent an actual enrolled sample.

Flaxseed-enriched chapati reduced triglycerides by 45 ± 24 mg/dL compared with 7 ± 21 mg/dL after standard chapati ($p<0.001$).

Table 1. Baseline characteristics

Characteristic	Intervention	Control	p-value
Participants (n)	45	45	—
Age (years)	42.8 ± 7.4	46.1 ± 7.1	0.78
Female n (%)	25 (56.0)	24 (55.0)	0.91
BMI (kg/m²)	27.8 ± 2.9	27.6 ± 3.1	0.74
Primary endpoint at baseline	214.0 ± 25.7	211.0 ± 25.3	0.83

Values are dummy/example data presented as mean ± SD unless otherwise stated.

The direction of the primary effect was supported by changes in LDL cholesterol and HDL cholesterol. The size of response tended to be more with exposure to the interventions or it was larger at the follow-up in the intervention arm as compared to the comparator. In cases where repeated measures existed, the group -time or condition effect was significant when the baseline values were taken into consideration and the multiple comparisons were planned.

Table 2. Primary and key secondary outcomes

Outcome	Intervention baseline	Intervention end	Control baseline	Control end	p for interaction
Triglycerides (mg/dL)	214.0 ± 25.7	169.0 ± 20.3	211.0 ± 25.3	204.0 ± 24.5	<0.001
LDL-C (mg/dL)	142.0 ± 14.2	124.0 ± 12.4	140.0 ± 14.0	137.0 ± 13.7	0.003
systolic blood pressure	100 ± 12	86 ± 11	99 ± 13	96 ± 12	0.011

Values are dummy/example data presented as mean ± SD unless otherwise stated.

LDL cholesterol fell by 18 mg/dL, hs-CRP by 0.8 mg/L, and systolic pressure by 5.6 mmHg in the intervention group, with 92% adherence.



Figure 1. Primary outcome based on dummy/example data.

Exploratory analyses indicated that the response in serum triglycerides was associated with the most relevant mechanistic marker. The pattern was consistent with alpha-linolenic acid, lignans, and viscous fiber acting on lipid metabolism, bile-acid handling, and vascular inflammation. No extreme value altered the direction of the result in sensitivity analysis. For clinical and food studies, adherence and acceptability remained within predefined feasibility limits; for laboratory studies, replicate variation and control performance remained within the planned analytical range.

Table 3. Adherence, acceptability, and safety

Outcome	Intervention	Control	p-value
Adherence (%)	92.4 ± 5.8	91.7 ± 6.1	0.58
Overall acceptability / 9	7.4 ± 0.8	7.6 ± 0.7	0.21
Mild gastrointestinal events n (%)	3 (6.7)	2 (4.4)	0.64
Serious adverse events	0	0	—
Participants completing study	43 (95.6)	43 (95.6)	0.98

Values are dummy/example data presented as mean ± SD unless otherwise stated.

Natural Resources for Human Health
eISSN: 2583-1194



Figure 2. Secondary or mechanistic outcome based on dummy/example data.

No unexpected safety signal was present in the example dataset. Mild events or assay artifacts were infrequent and balanced, and there were no serious adverse events, unplanned deaths, contamination failures, or invalid control runs unless explicitly shown in the tables. These observations are illustrative and must not be interpreted as evidence of real-world safety.

4. DISCUSSION

The present manuscript-development study indicates that two daily chapatis enriched with 20 g milled flaxseed may improve serum triglycerides compared with isocaloric standard wheat chapatis. The dummy findings were strengthened by concordant changes in LDL cholesterol, HDL cholesterol, and systolic blood pressure. This consistency within is significant since consistency between functional and mechanistic final points is less likely to indicate specific analytical anomaly.

The trend of the major outcome is generally comparable to other published studies on standardized botanical or food-based interventions related to models [9]. Even though protocols and populations vary, that literature equally shows that the preparation quality and dose can have a significant effect on the magnitude of the response.

Similar researches have also shown alterations in multidimensional evaluation in terms of inflammatory, oxidative, metabolic, microbial, structural, or functional results instead of using a single surrogate marker [10]. The current trend thus aligns to a broader body of evidence whilst being specific to the intervention and the model under study.

The mechanistic explanation is also supported by the studies which prove that complex interventions can work via convergent pathways and effects which depend on the matrix [11]. In this research, the correlation between the primary response and supporting markers was consistent with alpha-linolenic acid, lignans and viscous fibre in their effect on lipid metabolism, bile-acid management and vascular inflammation, but these associations alone do not identify which one is active.

Previous studies with similar endpoints further indicate the clinical or biological significance of LDL cholesterol and HDL cholesterol [12]. Their parallel improvement supports the hypothesis, and confirmatory research in the future needs to prespecify the use of these variables as secondary outcomes, mechanistic mediators, or exploratory biomarkers.

The example effect size must be viewed in terms of previous intervention studies and evidence reviews in the field more generally [13]. The size was deliberately realistic and with overlap among individuals or replicates since pilot effects often decline with testing in larger independent samples.

Methodological evidence discusses the significance of standardised measurement, suitable comparison conditions and clear reporting in research of complex interventions [14]. Bias can be minimized by replication, allocation concealment, blinded assessment, crossover control or validated analytical calibration but none can eliminate all sources of error.

Other factors that determine long-term translation include tolerability, quality assurance, product stability, adherence and interactions with habitual diet or medication. The published safety and implementation literature justifies considering these factors and efficacy as opposed to following a positive primary outcome has been achieved [15].

There are a number of limitations to the study. To begin with, the numerical information is exemplary and cannot be a scientific argument. Second, the suggested sample and time might fail to detect rare negative incidents or protracted adaptations. Third, surrogate outcomes may not necessarily translate into patient-important benefits. Fourth, response may be altered by unmeasured dietary, genetic, microbial, environmental, harvest or manufacturing factors.

These are some of the factors that should be included in future research, besides independent analytical confirmation, dose-ranging and preregistration, power and a statistical analysis plan. Ethics approval, trial registration, allocation procedures, adherence and intention-to-treat analysis must be recorded in clinical studies. Preclinical studies should include randomisation, blinding, humane endpoints, exclusions and batch level chemical fingerprints.

By this, imbedding flaxseed in a traditional staple could have an added benefit in terms of long-term adherence and population relevance from a translational standpoint. The intervention should also be looked upon as a possible complimentary or research-based intervention, not as an alternative to existing treatment. Further development should be considered based on replication, safety, cost, standardization, acceptability and comparison with available alternatives.

In general, the findings in the example support the study hypothesis and are structured together for a real investigation. All numerical results, ethics statement, registration details, disclosures and analyses should be replaced and verified with the actual study record prior to submission of the study and prior to publication.

5. CONCLUSION

With the use of dummy/example data, two chapatis made with 20g milled flaxseed each showed a beneficial effect on serum triglycerides, while there were positive changes in LDLc, HDLc and systolic blood pressure compared to isocaloric standard wheat chapatis, in this complete manuscript draft. The pattern was similar to alpha-linolenic acid, lignans and viscous fibre on lipid metabolism, handling of bile-acids and vascular inflammation, and had potential relevance, as embedding flaxseed into a traditional staple could enhance long-term adherence and population relevance. The draft offers a framework for drafting the protocol, planning the collection of data and, subsequently, the preparation of the manuscript but is not meant to be a substitute for data that has been ethically generated and independently verified, before it can be presented as original research.

Declarations for Completion Before Submission

Ethics approval: Insert the actual institutional ethics committee name, approval number, approval date, and relevant consent or animal-welfare statement.

Trial registration: Insert the registry name and number for prospective clinical trials, where applicable.

Funding: Insert the verified funding source or state that no specific funding was received.

Conflicts of interest: Insert author-specific conflict-of-interest disclosures.

Data availability: Describe where the actual de-identified dataset and analysis code will be available.

Author contributions: Insert contribution statements using an accepted taxonomy such as CRediT.

REFERENCES

[1] Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019;393(10170):434-445. doi:10.1016/S0140-6736(18)31809-9. PMID:30638909.

[2] Pan A, Chen M, Chowdhury R, et al. Alpha-linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2012;96(6):1262-1273. doi:10.3945/ajcn.112.044040. PMID:23076616.

[3] Yang C, Xia H, Wan M, et al. Comparisons of the effects of different flaxseed products consumption on lipid profiles, inflammatory cytokines and anthropometric indices in patients with dyslipidemia: a systematic review and dose-response meta-analysis. Nutr Metab (Lond). 2021;18:91. PMID:34635132.

[4] Saxena S, Katare C. Evaluation of flaxseed formulation as a potential therapeutic agent in mitigation of dyslipidemia. Biomed J. 2014;37(6):386-390. PMID:25163498.

[5] Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-183. doi:10.1016/j.redox.2015.01.002. PMID:25588755.

[6] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. doi:10.3389/fphar.2013.00177. PMID:24454289.

[7] Siervo M, Lara J, Ogbonmwan I, Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr. 2013;143(6):818-826. doi:10.3945/jn.112.170233. PMID:23596162.

[8] Zare M, Goli AH, Karimifar M, Tarrahi MJ, Rezaei A, Amani R. Effect of bread fortification with pomegranate peel powder on glycemic indicators, antioxidant status, inflammation and mood in patients with type 2 diabetes: study protocol for a randomized triple-blind placebo-controlled trial. J Diabetes Metab Disord. 2023;22(1):921-929. doi:10.1007/s40200-022-01168-z. PMID:36628115.

[9] Fenercioglu AK, Saler T, Genc E, Sabuncu H, Altuntas Y. Effects of polyphenol-containing antioxidants on oxidative stress and lipid peroxidation in type 2 diabetes mellitus without complications. J Endocrinol Invest. 2010;33(2):118-124. doi:10.1007/BF03346565. PMID:19834314.

[10] Jenkins DJA, Wolever TMS, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34(3):362-366. doi:10.1093/ajcn/34.3.362. PMID:6259925.

[11] Brouns F, Bjorck I, Frayn KN, et al. Glycaemic index methodology. Nutr Res Rev. 2005;18(1):145-171. doi:10.1079/NRR2005100. PMID:19079901.

[12] Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005;53(10):4290-4302. doi:10.1021/jf0502698. PMID:15884874.

[13] Ayaz A, Akyol A, Inan-Eroglu E, Kabasakal Cetin A, Samur G, Akbiyik F. Chia seed added yogurt reduces short-term food intake and increases satiety: randomized controlled trial. Nutr Res Pract. 2017;11(5):412-418. doi:10.4162/nrp.2017.11.5.412. PMID:28989578.

[14] Ho H, Lee AS, Jovanovski E, Jenkins AL, DeSouza R, Vuksan V. Effect of whole and ground Salba seeds on postprandial glycemia in healthy volunteers: a randomized controlled dose-response trial. Eur J Clin Nutr. 2013;67(7):786-788. doi:10.1038/ejcn.2013.103.

[15] Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN. Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am J Clin Nutr. 2005;82(3):559-567. PMID:16155268.